1Albet HF, Suessenbacher A, Weidinger F. The role of inflammation in the pathophysiology of acute coronary syndromes[J ]. Wiener Klinisthe Wochenschrift, 2005,117(13 - 14) :445 - 455.
2Heeschen C, Dimmeler S, Haren C, et al. Soluble CD40L in acute coronary, syndrome[ J ]. N Eng J Med, 2003,348 : 1104 - 1111.
3Chakrabarti S, Varghese S, Vitseva O, et al. CD40 ligand influences platelet release of reactive oxygen intermediates[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005,25 (11 ) : 2428 - 2434.
5Nabhavi M, Libby P, Falk E, et al. From vulenrable plaque to vulnerable patient:A cell for new definitions and risk assessment strategies[J ]. Circulation, 2003,108(15) : 1772 - 1778.
7Chai H, Yan S, Wang H, et al. CD40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells [ J ]. Surgery, 2006,140(2) : 236 - 242.
8Liang KW, Sheu WH, Lee WL, et al. Coronary artery disease progression is associated with C - reactive protein and conventional risk factors but not soluble CD40 ligand[J ]. The Canadian Journal of Cardiology,2006,22 (8) :691 - 696.
9Lemos JA,Blazing MA,Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:Phase Z of the A to Z trial[J]. JAMA, 2004,292 (11):1307.
5Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s[J]. Nature, 1993, 362: 801-809.
6Horton DB, Libby P, Schonbeck U. Ligation of CD40 on vascular smooth muscle cells mediates loss of interstitial collagen via matrix metalloproteinase activity[J]. Ann N Y Acad Sci,2001,947: 329-336.
7Wagner AH, Gebauer M, Guldenzoph B. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells[J]. Arterioscler Thromb Vasc Biol,2002,22(11): 1784-1789.
8Phipps RP, Koumas L, Leung E, et al. The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis[J]. Curr Opin Investig Drugs,2001,2(6): 773-777.
9Carbone E, Ruggiero G,Terrazzano G, et al. Cell cytotoxicity activation: the CD40-CD40 Ligand interaction.J Exp Med 1997:185(12):2053-60
10Wei RT,Jonakait GM,Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4),IL-10,IL-11 and transforming growth factor-β1 (TGF-31) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat mi-croglia. J Neuroimmunol 1999;95(1-2): 8-18
2Ross R.Ather osclerosis is an inflammatory disease[J].Am Heart J,1999,138 (5 Pt 2):S419.
3Madadi P,Hiladebranat D.Ross R1At herosclerosis is an inflammatory disease[J].Am Heart J,1999,138:419-420.
4Wick G,Xu Q1.At herosclerosis is a paradigmatic disease of the elderly,the roots of which are laid in youth,whereas the clinically manifested consequences become evident at old age[J].Exp Gerontol,1999,34:559-566.
5Yamauchi T,Kamon J,Mizo KY,et al.Adiponectin stimulates glucose utilization and fattyacid oxidation by activating AMP-activated protein kinase[J].Nat Med,2002,8:1288-1295.
6Gensini GG.A more meaningful scoring system for determing the severity of coronary heart disease[J].Am J Cardiol,1983,51:606.
7Bruemmer D,Riggers U,Holzmeister J,et al.Exp ression of CD40 in vascularsmooth muscle cells andmacrophages is associated with early developmentof human atherosclerotic lesions[J].Am J Cardiol,2001,87 (1):21227.
8Arita Y,Kihara S,Ouchi N,et al.Paradoxical decrease of an adipose specific protein,adiponectin,in obesity[J].Biochem Biophys Res Commun,1999,257:79-83.
9Ouchi N,Kihara S,Arita Y,et al.Adipocyte2derived plasma protein,adiponectin,suppresses 1ipid accumulation and class A scavenger receptor expression in human monocyte2derived macrophages[J].Circulation,2001,103:1057-1063.
10Fruebis J,Tsao TS,Javorschi S,et al.Proteolytic cleavage product of 302KDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice[J].Proc Nat Acad Sci USA,2001,98:2005-2010.
